Natural History of Clinically Staged Low- and Intermediate-Risk Prostate Cancer Treated With Monotherapeutic Permanent Interstitial Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 2, 2010, Pages 349-354

  Taira, Al V ^a   Merrick, Gregory S ^b   Galbreath, Robert W ^b   Wallner, Kent E ^c   Butler, Wayne M ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biochemical progression free survival; Brachytherapy; Cause specific survival; Prostate cancer

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CAUSE-SPECIFIC SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HIGH QUALITY; IMPLANT QUALITY; INTERSTITIAL BRACHYTHERAPY; LOCALIZED PROSTATE CANCER; MONO-THERAPY; MULTIPLE PARAMETERS; NATURAL HISTORY; OVERALL SURVIVAL RATES; PRE-TREATMENT; PROGRESSION FREE SURVIVAL; PROSTATE CANCERS; PROSTATE GLANDS; PROSTATE SPECIFIC ANTIGEN; TARGET VOLUMES; TREATMENT OUTCOMES;

COMMUNICATION CHANNELS (INFORMATION THEORY); DOSIMETRY; ONCOLOGY;

RADIOTHERAPY;

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; COHORT ANALYSIS; DISEASE SEVERITY; DOSIMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIATION DOSE; TARGET ORGAN; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73649111724     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.02.021     Document Type: Article

References (30)

1. Bittner N., Merrick G.S., Galbreath R.W., et al. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 72 (2008) 433-440
2. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
3. Critz F.A., and Levinson K. 10-Year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 172 (2004) 2232-2238
4. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
5. Kao J., Stone N.N., Lavaf A., et al. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys 70 (2008) 96-101
6. Sharkey J., Cantor A., Solc Z., et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: A 12-year experience from a single group practice. Brachytherapy 4 (2005) 34-44
7. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
8. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
9. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110 (2007) 551-555
10. Merrick G.S., and Butler W.M. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol 6 (2000) 78-84
11. Butler WM, Stewart RR, Merrick GS. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case control study of permanent prostate brachytherapy patients. Med Phys. In press.
12. Nath R, Bice W, Butler WM, et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer. Med Phys. In press.
13. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
14. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1487-1493
15. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
16. Stock R.G., Stone N.N., Dahlal M., et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy 1 (2002) 83-89
17. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
18. Stone N.N., Stock R.G., and Unger P. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol 173 (2005) 803-807
19. Hernandez D.J., Nielsen M.E., Han M., et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 72 (2008) 172-176
20. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
21. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167 (2002) 528-534
22. Kupelian P.A., Elshaikh M., Reddy C.A., et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20 (2002) 3376-3385
23. Wallner K., Merrick G., Blasko J.C., et al. Prostate brachytherapy made complicated. 3rd ed (2008), SmartMedicine Press, Seattle
24. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
25. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
26. Roach III M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-591
27. Stone N.N., Potters L., Davis B.J., et al. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 69 (2007) 1472-1477
28. Stone N.N., Potters L., Davis B.J., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason Score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73 (2009) 341-346
29. Merrick G.S., Butler W.M., Wallner K.E., et al. Dosimetry of an extracapsular anulus following permanent prostate brachytherapy. Am J Clin Oncol 30 (2007) 228-233
30. Merrick G.S., Butler W.M., Wallner K.E., et al. Extracapsular radiation dose distribution after permanent prostate brachytherapy. Am J Clin Oncol 26 (2003) e178-e189